ITM Isotope Technologies to Engage Investors at Major Conferences
ITM Isotope Technologies Munich SE (ITM), a pioneer in the field of radiopharmaceuticals, has exciting updates for investors. The company is gearing up to participate in several key industry conferences. Dr. Andrew Cavey, the Chief Executive Officer, is set to represent ITM through multiple virtual sessions and in-person meetings, emphasizing the company's commitment to moving the radiopharmaceutical sector forward.
Conference Participation Highlights
This month, ITM will feature prominently during several prestigious investor engagements. Notably, Dr. Cavey will showcase ITM's innovative efforts during a series of fireside chats, providing investors with an in-depth look at the company's projects and future endeavors.
William Blair Virtual Radiopharma Conference
On November 13, 2025, Dr. Cavey will attend the William Blair Virtual Radiopharma Conference. He will take part in a virtual fireside chat at 11:00 am ET / 5:00 pm CET. This event is a perfect opportunity for investors to gain insights into ITM's latest developments.
Jefferies London Healthcare Conference
Following that, from November 17 to 19, 2025, Dr. Cavey, along with Dr. Klaus Maleck, the Chief Financial Officer, will be present at the Jefferies London Healthcare Conference 2025. During this time, they will engage in one-on-one meetings with conference attendees, fostering direct connections and discussions about ITM's strategies and products.
Brookline Capital Markets Fireside Chat
On December 16, 2025, there's another opportunity for interaction at the Brookline Capital Markets Fireside Chat, where Dr. Cavey will join a virtual discussion at 9:00 am ET / 3:00 pm CET. This chat is poised to delve into ITM's mission and future projects, focusing on their innovative oncology pipeline.
Contact Information for Investors
For any investor inquiries, it's essential to have the right contact details. Investors can reach out to:
ITM Investor Relations
Ben Orzelek
Phone: +49 89 329 8986 1009
Email: investors@itm-radiopharma.com
ITM Corporate Communications
Kathleen Noonan/Julia Westermeir
Phone: +49 89 329 8986 1500
Email: communications@itm-radiopharma.com
About ITM Isotope Technologies Munich SE
ITM is dedicated to developing cutting-edge radiopharmaceutical therapeutics and diagnostics targeted at challenging tumors. With a strong commitment to improving patient outcomes, ITM focuses on the development, production, and supply of essential medical radioisotopes. The company is advancing a robust pipeline in precision oncology, which includes multiple phase 3 studies, leveraging its high-quality radioisotopes and diverse targeting molecules. With over two decades of experience, ITM positions itself at the forefront of the industry, working to enhance the quality of life for cancer patients globally.
Frequently Asked Questions
What is ITM Isotope Technologies Munich SE?
ITM is a leading biotech company specializing in radiopharmaceuticals aimed at treating difficult tumors.
Who is participating in the upcoming conferences?
ITM's CEO Dr. Andrew Cavey and CFO Dr. Klaus Maleck will participate in various conferences.
When is the William Blair Virtual Radiopharma Conference?
The conference will be held on November 13, 2025, at 11:00 am ET / 5:00 pm CET.
How can investors contact ITM for inquiries?
Investors can reach ITM's Investor Relations via email at investors@itm-radiopharma.com.
What is ITM's focus in oncology?
ITM focuses on developing advanced diagnostics and therapeutics for challenging cancer cases to improve treatment outcomes.
